SCHEMBL22275503

SCHEMBL22275503

Cc1nc2cccc(C)n2c1CO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.50
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 4/20 0.41
POLB P06746 3/20 0.41
CYP1A2 P05177 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
PKM P14618 3/20 0.40
LMNA P02545 1/20 0.40
RAB9A P51151 1/20 0.40
TP53 P04637 4/20 0.38
PKLR P30613 1/20 0.38
RXFP1 Q9HBX9 1/20 0.36
GAA P10253 6/20 0.36
MAPT P10636 2/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
SMN1; SMN2 Q16637 5/20 0.34
ATP4A P20648 1/20 0.34
ATP4B P51164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18754397 0.75 HTT (0.58) HTTALDH1A1KDM4EPOLBCYP1A2
SCHEMBL22275506 0.74 DRD2 (0.35) ALDH1A1KDM4EATP4AATP4BPDE10A
SCHEMBL16506289 0.72 HTT (0.54) HTTALDH1A1KDM4EPOLBCYP1A2
SCHEMBL859998 0.71 KDM4E (0.65) HTTALDH1A1KDM4EHPGDGAA
SCHEMBL4772682 0.70 KMT2A (0.57) HTTALDH1A1KDM4EPOLBCYP1A2
SCHEMBL7829888 0.70 HTT (0.53) HTTALDH1A1KDM4EPOLBCYP1A2
SCHEMBL22275564 0.69 KDM4E (0.37) HTTALDH1A1KDM4EPKMLMNA
SCHEMBL21849002 0.69 HTT (0.51) HTTALDH1A1KDM4EPOLBCYP1A2
SCHEMBL13833739 0.69 HTT (0.56) HTTALDH1A1KDM4EPOLBCYP1A2
SCHEMBL21863678 0.69 HTT (0.51) HTTALDH1A1KDM4EPOLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2020-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME CXCR4, CXCL12, CXCR1 HTT 1844/4885ALDH1A1 1506/4885KDM4E 4466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.